---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-163507"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:55:04.119250+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Enliven shareholders approve 2.9M share increase in equity plan and officer exculpation amendment

## Summary
- Stockholders approved amendment to 2020 Equity Incentive Plan, increasing authorized shares by 2,900,000.
- Certificate of Incorporation amended to limit officer liability for monetary damages under Delaware law.
- Class I directors Mika Derynck (36.4M for) and Rishi Gupta (37.4M for) elected to 2027 annual meeting.
- Deloitte & Touche LLP ratified as independent auditor for FY 2024 with 42.9M votes for.
- All proposals passed; broker non-votes 4.6M on director elections and other items.

## SEC filing metadata
- accession: 0001193125-24-163507
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312524163507/0001193125-24-163507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312524163507/d853800d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-163507
- JSON: https://secwatch.observer/filing/0001193125-24-163507.json
- Plain text: https://secwatch.observer/filing/0001193125-24-163507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.